A post on stock market information Website Seeking Alpha says Johnson & Johnson will likely deal with significant public backlash going forward. An Arkansas jury recently concluded that the company used deceptive tactics to market antipsychotic drug Risperdal, which included hiding or minimizing the drug’s risks. A judge then issued a $1.2 billion fine.
The post says the fine leveled against Johnson and Johnson and subsidiary Janssen Pharmaceuticals is the largest ...
continue reading...